Non-Small Cell Lung Cancer with EGFR Mutations

The Non-Small Cell Lung Cancer with EGFR Mutations pipeline: 2 tracked drugs.

Coverage in progress. The assets here come from their companies' published pipelines. AssetMemo has not yet run its full census of every drug in development for Non-Small Cell Lung Cancer with EGFR Mutations, so this list is not complete.

1 Phase 1/21 preclinical / unstaged

Market size not yet sourced. How markets are sized ↗

The Non-Small Cell Lung Cancer with EGFR Mutations pipeline

← all assets